NO20030081L - Anvendelse av stammer fra parapoxvirus mot organfibroser - Google Patents

Anvendelse av stammer fra parapoxvirus mot organfibroser

Info

Publication number
NO20030081L
NO20030081L NO20030081A NO20030081A NO20030081L NO 20030081 L NO20030081 L NO 20030081L NO 20030081 A NO20030081 A NO 20030081A NO 20030081 A NO20030081 A NO 20030081A NO 20030081 L NO20030081 L NO 20030081L
Authority
NO
Norway
Prior art keywords
organ fibrosis
strains against
against organ
parapoxvirus
parapoxvirus strains
Prior art date
Application number
NO20030081A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030081D0 (no
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20030081D0 publication Critical patent/NO20030081D0/no
Publication of NO20030081L publication Critical patent/NO20030081L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030081A 2000-07-11 2003-01-08 Anvendelse av stammer fra parapoxvirus mot organfibroser NO20030081L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (fr) 2000-07-11 2001-07-11 Utilisation de souches du virus parapox ovis contre la fibrose des organes

Publications (2)

Publication Number Publication Date
NO20030081D0 NO20030081D0 (no) 2003-01-08
NO20030081L true NO20030081L (no) 2003-01-08

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030081A NO20030081L (no) 2000-07-11 2003-01-08 Anvendelse av stammer fra parapoxvirus mot organfibroser

Country Status (30)

Country Link
US (1) US6632647B2 (fr)
EP (1) EP1303302B1 (fr)
JP (1) JP5106736B2 (fr)
CN (1) CN1452496B (fr)
AR (1) AR028800A1 (fr)
AU (2) AU8582701A (fr)
BG (1) BG107447A (fr)
CA (1) CA2415399C (fr)
CZ (1) CZ200372A3 (fr)
DK (1) DK200300014A (fr)
EE (1) EE200300019A (fr)
FI (1) FI20030038A7 (fr)
GB (1) GB2383752B (fr)
HK (1) HK1054330B (fr)
HR (1) HRP20030097A2 (fr)
HU (1) HU227668B1 (fr)
IL (1) IL153826A0 (fr)
LT (1) LT5064B (fr)
LU (1) LU90996B1 (fr)
LV (1) LV12991B (fr)
MA (1) MA25765A1 (fr)
MX (1) MXPA03000278A (fr)
NO (1) NO20030081L (fr)
NZ (1) NZ523535A (fr)
PL (1) PL360839A1 (fr)
RU (1) RU2003104522A (fr)
SE (1) SE0300033L (fr)
SI (1) SI21171A (fr)
SK (1) SK382003A3 (fr)
WO (1) WO2002004019A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6844000B2 (en) 2001-12-07 2005-01-18 Bayer Pharmaceuticals Corporation Use of Parapox B2L protein to treat cancer and modify immune responses
EP1574211A1 (fr) * 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
WO2012045473A1 (fr) * 2010-10-07 2012-04-12 Technische Universität München Virus pour le traitement d'une fibrose
JP6875745B2 (ja) * 2016-02-16 2021-05-26 国立大学法人大阪大学 線維化を治療するための医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK0885013T3 (da) * 1996-04-15 2001-11-05 Anton Prof Dr Med Vet Dr Mayr Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
GB2383752B (en) 2004-11-24
LV12991B (en) 2003-08-20
DK200300014A (da) 2003-03-07
HK1054330A1 (en) 2003-11-28
CN1452496A (zh) 2003-10-29
NZ523535A (en) 2004-12-24
LU90996B1 (en) 2003-01-08
GB0302629D0 (en) 2003-03-12
IL153826A0 (en) 2003-07-31
SE0300033D0 (sv) 2003-01-10
WO2002004019A2 (fr) 2002-01-17
SK382003A3 (en) 2003-07-01
MA25765A1 (fr) 2003-04-01
AU2001285827B2 (en) 2006-11-30
US20020076418A1 (en) 2002-06-20
HRP20030097A2 (en) 2005-02-28
WO2002004019A3 (fr) 2002-08-01
CA2415399A1 (fr) 2003-01-08
CZ200372A3 (cs) 2003-05-14
US6632647B2 (en) 2003-10-14
CA2415399C (fr) 2011-11-08
RU2003104522A (ru) 2004-06-27
BG107447A (bg) 2003-09-30
FI20030038A7 (fi) 2003-03-10
EE200300019A (et) 2004-10-15
HUP0303830A3 (en) 2004-10-28
AR028800A1 (es) 2003-05-21
CN1452496B (zh) 2012-10-10
LT2003008A (en) 2003-07-25
LT5064B (lt) 2003-11-25
NO20030081D0 (no) 2003-01-08
EP1303302A2 (fr) 2003-04-23
PL360839A1 (pl) 2004-09-20
HU227668B1 (en) 2011-11-28
JP2004502741A (ja) 2004-01-29
HK1054330B (zh) 2005-07-15
SI21171A (sl) 2003-10-31
HUP0303830A2 (hu) 2004-04-28
MXPA03000278A (es) 2004-04-05
SE0300033L (sv) 2003-03-10
GB2383752A (en) 2003-07-09
AU8582701A (en) 2002-01-21
JP5106736B2 (ja) 2012-12-26
EP1303302B1 (fr) 2009-10-14

Similar Documents

Publication Publication Date Title
CY1105127T1 (el) Συνθεση για την προληψη καρδιαγγειακων νοσων
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
MXPA05007513A (es) Compuestos, composiciones y metodos.
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DE60141703D1 (de) Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose
EA201100755A1 (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2003059258A3 (fr) Compositions et methodes permettant de traiter l'insuffisance cardiaque
AR037556A1 (es) Composicion farmaceutica que comprende un abridor del canal de c1c-2
NO20030081L (no) Anvendelse av stammer fra parapoxvirus mot organfibroser
NZ623674A (en) Vip fragments and methods of use
CR9073A (es) Coadministracion de tigeciclina y digoxin
NO20056218L (no) Substituerte pyrrolderivater og anvendelse derav som HMF-CoA reduktase-inhibitorer
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
UA85232C2 (ru) Оксабиспидиновые соединения и их применение в лечении сердечных аритмий
Spinney Snakes in suits.
RU2002118824A (ru) Бальнеологическое лечебно-профилактическое средство "Бишоль"

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application